TY - JOUR T1 - SARS-CoV-2 show no infectivity at later stages in a prolonged COVID-19 patient despite positivity in RNA testing JF - medRxiv DO - 10.1101/2021.03.18.21253228 SP - 2021.03.18.21253228 AU - Xiu-Feng Wan AU - Cynthia Y. Tang AU - Detlef Ritter AU - Yang Wang AU - Tao Li AU - Karen Segovia AU - Martina Kosikova AU - Marc Johnson AU - Hyung Joon Kwon AU - Hang Xie AU - Richard D. Hammer AU - Jane A. McElroy AU - Aws Hamid AU - Natalie D Collins AU - Jun Hang AU - Simone Camp Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/20/2021.03.18.21253228.abstract N2 - Inpatient COVID-19 cases present enormous costs to patients and health systems. Many hospitalized patients may still test COVID-19 positive, even after resolution of symptoms. Thus, a pressing concern for clinicians is the safety of discharging these asymptomatic patients if they have any remaining infectivity. This case report explores the viral viability in a patient with persistent COVID-19 over the course of a two-month hospitalization. Positive nasopharyngeal swab samples, analyzed by quantitative reverse transcription polymerase chain reactions (qRT-PCR), were collected and isolated in the laboratory, and infectious doses were analyzed throughout the hospitalization period. The patient experienced waning symptoms by hospital day 40 and had no viable virus growth in the laboratory by hospital day 41, suggesting no risk of infectivity, despite positive RT-PCR results, which prolonged his hospital stay. Notably, this case showed infectivity for at least 24 days from disease onset, which is longer than the discontinuation of transmission-based precautions recommendation by CDC. Thus, our findings suggest that the timeline for discontinuing transmission-based precautions may need to be extended for patients with prolonged illness. Additional large-scale studies are needed to draw definitive conclusions on the appropriate clinical management for these patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Institutes of Health [5T32LM012410] and Global Emerging Infections Surveillance Branch of the Armed Forces Health Surveillance Division [ProMIS ID P0140_20_WR_01.Global]. The authors have no conflicts of interest to report. The opinions or assertions contained herein are the private views of the authors, and are not to be construed as official, or as reflecting true views of the US Department of the Army, the US Department of Defense, the US Department of Health and Human Services, or University of Missouri-Columbia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Missouri-Columbia Institutional Review Board (#2023844) and at the Institutional Biosafety Committee Biosafety Level 3 (#20-14).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request from the authors ER -